CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 267 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04844918
NCT04844918Phase 3Completed
CompareCT.gov

Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)

Eli Lilly and Company·interventional·Posted Apr 14, 2021·Updated Jul 16, 2024

In Brief

A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Obesity. Completed, enrolled 267 participants across 18 sites.

Detailed Summary

The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedApr 14, 2021
Enrollment StartMay 10, 2021
Primary CompletionJun 24, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.2 years ago

Interventions

Tirzepatidedrug

Administered SC

Placeboother

Administered SC